AAAAAA

   
Results: 1-24 |
Results: 24
Anti-HIV type 1 activity of 3 '-fluoro-3 '-deoxythymidine for several different multidrug-resistant mutants
Authors: Kim, EY Vrang, L Oberg, B Merigan, TC
Citation: Ey. Kim et al., Anti-HIV type 1 activity of 3 '-fluoro-3 '-deoxythymidine for several different multidrug-resistant mutants, AIDS RES H, 17(5), 2001, pp. 401-407
Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4(+) T cell counts of <= 500 and 200-400/mm(3) (AIDS Clinical Trials Group study 246/946)
Authors: Kundu-Raychaudhuri, S Sevin, A Kilgo, P Nokta, M Pollard, RB Merigan, TC
Citation: S. Kundu-raychaudhuri et al., Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4(+) T cell counts of <= 500 and 200-400/mm(3) (AIDS Clinical Trials Group study 246/946), AIDS RES H, 17(15), 2001, pp. 1371-1378
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samplesfrom heavily treated patients
Authors: Shafer, RW Hertogs, K Zolopa, AR Warford, A Bloor, S Betts, BJ Merigan, TC Harrigan, R Larder, BA
Citation: Rw. Shafer et al., High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samplesfrom heavily treated patients, J CLIN MICR, 39(4), 2001, pp. 1522-1529
Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs
Authors: Winters, MA Merigan, TC
Citation: Ma. Winters et Tc. Merigan, Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs, ANTIM AG CH, 45(8), 2001, pp. 2276-2279
Functional correlates of insertion mutations in the protease gene of humanimmunodeficiency virus type 1 isolates from patients
Authors: Kim, EY Winters, MA Kagan, RM Merigan, TC
Citation: Ey. Kim et al., Functional correlates of insertion mutations in the protease gene of humanimmunodeficiency virus type 1 isolates from patients, J VIROLOGY, 75(22), 2001, pp. 11227-11233
Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens
Authors: Winters, MA Baxter, JD Mayers, DL Wentworth, DN Hoover, ML Neaton, JD Merigan, TC
Citation: Ma. Winters et al., Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens, ANTIVIR TH, 5(1), 2000, pp. 57-63
In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients
Authors: Shapero, MH Kundu, SK Engleman, E Laus, R van Schooten, WCA Merigan, TC
Citation: Mh. Shapero et al., In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients, CELL TRANSP, 9(3), 2000, pp. 307-317
Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activatedT cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8(+) T cells
Authors: Gray, CM Lawrence, J Ranheim, EA Vierra, M Zupancic, M Winters, M Altman, J Montoya, J Zolopa, A Schapiro, J Haase, AT Merigan, TC
Citation: Cm. Gray et al., Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activatedT cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8(+) T cells, AIDS RES H, 16(14), 2000, pp. 1357-1369
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
Authors: Baxter, JD Mayers, DL Wentworth, DN Neaton, JD Hoover, ML Winters, MA Mannheimer, SB Thompson, MA Abrams, DI Brizz, BJ Ioannidis, JPA Merigan, TC
Citation: Jd. Baxter et al., A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy, AIDS, 14(9), 2000, pp. F83-F93
Genotypic, phenotypic, and modeling studies of a deletion in the beta 3-beta 4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors
Authors: Winters, MA Coolley, KL Cheng, P Girard, YA Hamdan, H Kovari, LC Merigan, TC
Citation: Ma. Winters et al., Genotypic, phenotypic, and modeling studies of a deletion in the beta 3-beta 4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors, J VIROLOGY, 74(22), 2000, pp. 10707-10713
Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS clinical trials groups 209 and 214
Authors: Schooley, RT Spino, C Kuritzkes, D Walker, BD Valentine, FT Hirsch, MS Cooney, E Friedland, G Kundu, S Merigan, TC McElrath, MJ Collier, A Plaeger, S Mitsuyasu, R Kahn, J Haslett, P Uherova, P deGruttola, V Chiu, S Zhang, B Jones, G Bell, D Ketter, N Twadell, T Chernoff, D Rosandich, M
Citation: Rt. Schooley et al., Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS clinical trials groups 209 and 214, J INFEC DIS, 182(5), 2000, pp. 1357-1364
Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen
Authors: Katzenstein, DA Kundu, S Spritzler, J Smoller, BR Haszlett, P Valentine, F Merigan, TC
Citation: Da. Katzenstein et al., Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen, J ACQ IMM D, 22(4), 1999, pp. 341-347
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
Authors: Palmer, S Shafer, RW Merigan, TC
Citation: S. Palmer et al., Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development, AIDS, 13(6), 1999, pp. 661-667
Clinical cross-resistance between the HIV-1 protease inhibitors saquinavirand indinavir and correlations with genotypic mutations
Authors: Schapiro, JM Winters, MA Lawrence, J Merigan, TC
Citation: Jm. Schapiro et al., Clinical cross-resistance between the HIV-1 protease inhibitors saquinavirand indinavir and correlations with genotypic mutations, AIDS, 13(3), 1999, pp. 359-365
Hydroxyurea enhances the activities of didanosine, 9-[2(phosphonylmethoxy)ethyl] adenine, and 9-[2(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates
Authors: Palmer, S Shafer, RW Merigan, TC
Citation: S. Palmer et al., Hydroxyurea enhances the activities of didanosine, 9-[2(phosphonylmethoxy)ethyl] adenine, and 9-[2(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates, ANTIM AG CH, 43(8), 1999, pp. 2046-2050
Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
Authors: Lawrence, J Schapiro, J Winters, M Montoya, J Zolopa, A Pesano, R Efron, B Winslow, D Merigan, TC
Citation: J. Lawrence et al., Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons, J INFEC DIS, 179(6), 1999, pp. 1356-1364
Antiviral activity of the human immunodeficiency virus type 1 specific nonnucleoside reverse transcriptase inhibitor HBY097 alone and in combination with zidovudine in a phase II study
Authors: Kleim, JP Winters, M Dunkler, A Suarez, JR Riess, G Winkler, I Balzarini, J Oette, D Merigan, TC
Citation: Jp. Kleim et al., Antiviral activity of the human immunodeficiency virus type 1 specific nonnucleoside reverse transcriptase inhibitor HBY097 alone and in combination with zidovudine in a phase II study, J INFEC DIS, 179(3), 1999, pp. 709-713
Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS Clinical Trials Group 229
Authors: Schapiro, JM Lawrence, J Speck, R Winters, MA Efron, B Coombs, RW Collier, AC Merigan, TC
Citation: Jm. Schapiro et al., Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS Clinical Trials Group 229, J INFEC DIS, 179(1), 1999, pp. 249-253
Frequency of class I HLA-restricted anti-HIV CD8(+) T cells in individualsreceiving highly active antiretroviral therapy (HAART)
Authors: Gray, CM Lawrence, J Schapiro, JM Altman, JD Winters, MA Crompton, M Loi, M Kundu, SK Davis, MM Merigan, TC
Citation: Cm. Gray et al., Frequency of class I HLA-restricted anti-HIV CD8(+) T cells in individualsreceiving highly active antiretroviral therapy (HAART), J IMMUNOL, 162(3), 1999, pp. 1780-1788
Impact of prophylactic immediate posttransplant ganciclovir on developmentof transplant atherosclerosis - A post hoc analysis of a randomized, placebo-controlled study
Authors: Valantine, HA Gao, SZ Menon, SG Renlund, DG Hunt, SA Oyer, P Stinson, EB Brown, BW Merigan, TC Schroeder, JS
Citation: Ha. Valantine et al., Impact of prophylactic immediate posttransplant ganciclovir on developmentof transplant atherosclerosis - A post hoc analysis of a randomized, placebo-controlled study, CIRCULATION, 100(1), 1999, pp. 61-66
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
Authors: Zolopa, AR Shafer, RW Warford, A Montoya, JG Hsu, P Katzenstein, D Merigan, TC Efron, B
Citation: Ar. Zolopa et al., HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed, ANN INT MED, 131(11), 1999, pp. 813
Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization
Authors: Kundu, SK Dupuis, M Sette, A Celis, E Dorner, F Eibl, M Merigan, TC
Citation: Sk. Kundu et al., Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization, AIDS RES H, 14(18), 1998, pp. 1669-1678
Use of PCR to measure HIV viral changes in drug-resistant genes in genitalfluids
Authors: Merigan, TC
Citation: Tc. Merigan, Use of PCR to measure HIV viral changes in drug-resistant genes in genitalfluids, J REPRO IMM, 41(1-2), 1998, pp. 177-185
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients (vol 128, pg 906, 1998)
Authors: Shafer, RW Winters, MA Palmer, S Merigan, TC
Citation: Rw. Shafer et al., Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients (vol 128, pg 906, 1998), ANN INT MED, 129(12), 1998, pp. 1083-1083
Risultati: 1-24 |